Genocea's vaccine programs are built around the ATLAS™ platform for the rapid discovery of T cell antigens. T cell antigens, specifically antigens that stimulate CD4 + and CD8 + T cells, are critical to generating disease-specific cellular immune response and long-term T cell memory. At the core of ATLAS™ is a high throughput screening process that mimics the natural mammalian immune response to protein antigens.